W. Wolf

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

R. Schmieder, E. Fronk, P. Bramlage, 2010, Vascular health and risk management.

Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide

R. Schmieder, E. Fronk, P. Bramlage, 2014, Clinical Drug Investigation.

Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care

R. Schmieder, J. Wasem, E. Fronk, 2010, Expert opinion on pharmacotherapy.

O R I G I N a L C L I N I C a L I N V E S T I G a T I O N Open Access

S. Willich, A. Gitt, A. Cohen, 2022 .

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

R. Schmieder, E. Fronk, P. Bramlage, 2014, Vascular health and risk management.

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

R. Schmieder, E. Fronk, P. Bramlage, 2013, Vascular health and risk management.

Health State In Patients With Venous Thromboembolism On Conventional And Non-Vka Oral Anticoagulants As Assessed With The Eq-5d-5l Questionnaire: Prefer In Vte Registry.

A. Gitt, G. Agnelli, M. Monreal, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry

S. Willich, A. Gitt, A. Cohen, 2015, Thrombosis Journal.